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            “Jokainen on oikeutettu mielipiteeseeni”
Tämän kirjan tarkoitus on osallistua sotaan apatiaa ja yksinäisyyttä vastaan.
Antoisia lukuhetkiä.
Abstract
The central themes of this thesis are mutations of the POLG1 gene encoding the
catalytic subunit of mitochondrial DNA polymerase gamma protein, pol , their
association with the wide spectrum of clinical phenotypes and tissue specificity
and the biochemical characterization of particular defective mutant variants in the
protein’s spacer region.
PolG-holoenzyme is the sole DNA polymerase found in mitochondria. It is
involved in replication and repair of the mitochondrial genome, mtDNA.
Holoenzyme also includes the accessory subunit pol , which is required for the
processivity of pol . Defective pol  causes accumulation of secondary
mutations on mtDNA, which leads to a defective oxidative phosphorylation
system. The clinical consequences of such mutations are variable, affecting
nervous system, skeletal muscles, liver and other post-mitotic tissues.
In 2001, three PEO (Progressive External Ophthalmoplegia) -families were
reported to carry either recessive or dominant mutations in the POLG1 gene.
Shortly thereafter, an Italian group found novel POLG1 mutations in several Italian
PEO-families. These findings prompted us to study the role of POLG1 in patients
with putative mitochondrial diseases.
The aims of the studies were:
1) Determination of the role of POLG1 mutations in neurological syndromes
with features of mitochondrial dysfunction and an unknown molecular cause.
2)  Development and set up of diagnostic tests for routine clinical purposes.
3) Biochemical characterization of the functional consequences of the
identified pol  variants.
Clinical, molecular genetic and biochemical studies were conducted. Clinical
examinations consisted of detailed neurological assessments including MRI and
PET scans. Most of the genetic studies were done with PCR-based methods,
including DNA sequencing, solid-phase minisequencing and denaturing high-
pressure liquid chromatography (dHPLC). Biochemical characterization was
accomplished with the aim of baculovirus-based recombinant protein expression
and subsequent purification. In vitro assays included polymerase activity, DNA
binding, and processivity measurements.
Studies describe new neurological phenotypes in addition to PEO caused by
POLG1 mutations, including parkinsonism, premature amenorrhea, ataxia and
Parkinson’s disease (PD). POLG1 mutations and polymorphisms are both
common and potential genetic risk factors at least among the Finnish population.
The major findings and applications reported here are:
1) POLG1 mutations cause parkinsonism and premature menopause in PEO
families in either a recessive or a dominant manner. (Study I)
2) The common recessive POLG1 mutations (A467T and W748S) in the
homozygous state causes severe adult or juvenile-onset spinocerebellar ataxia
without muscular symptoms or histological or mtDNA abnormalities in muscles.
(Study III)
3) A common recessive pathogenic change A467T can also cause a mild
dominant disease in heterozygote carriers. (Study IV)
4) The A467T variant shows reduced polymerase activity due to defective
template binding. (Study IV)
5) Rare polyglutamine tract length variants of POLG1 are significantly enriched
in Finnish idiopathic Parkinson’s disease patients. (Study II)
6) Dominant mutations are clearly restricted to the highly conserved
polymerase domain motifs, whereas recessive ones are more evenly
distributed along the pol  protein. (Studies I,III,IV)
The present results highlight and confirm the new role of mitochondria in
parkinsonism/Parkinson’s disease and describe a new mitochondrial ataxia.
Based on these results, a POLG1 diagnostic routine has been set up in Helsinki
University Central Hospital (HUSLAB).
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TWINKLE   mitochondrial DNA helicase
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Introduction
All human cells except red blood cells contain mitochondria. Mitochondria are
essential double-membrane cellular organelles that “live, divide and fuse” semi-
autonomously in an endosymbiotic relationship inside the cell. They contain their
own genome (mtDNA), encoding 13 proteins essential for their ATP production
function as well as 22 tRNAs and two ribosomal RNAs, which form part of the
organelle’s internal protein synthesis machinery. Human mtDNA is a ~16.6 kb
long intronless circular molecule, and its genetic code diverges from the universal
code.
Mitochondria contain more than 1000 proteins encoded by nuclear genes.
These are necessary to maintain the vital functions of both the organelle itself and
the whole cell, including energy conversion, biosynthesis of various molecules
(heme, nucleotides, amino acids and cholesterol), control of apoptosis, calcium
buffering and signalling. These proteins are expressed and synthesised outside
mitochondria and then imported from cytosol into the organelle through protein
transport complexes embedded in the mitochondrial membranes. Interestingly,
many of these nuclear-encoded proteins resemble their prokaryotic counterparts
(bacteria and bacterial viruses = bacteriophages) suggesting a prokaryotic origin
in addition to the bacterium-like structural features of mitochondria.
Currently, more than a hundred primary mtDNA mutations are known to cause
human diseases. Moreover, a growing number of nuclear gene defects are known
to cause mitochondrial disorders. The diseases known to date to be caused by
nuclear gene defects affecting mitochondria may manifest as symptoms involving
the central and peripheral nervous systems as well as the sensory organs, liver,
heart or skeletal muscle.
One of the key players in mtDNA replication and maintenance is the
mitochondrial DNA polymerase gamma, polG holoenzyme. Mutations in the
mitochondrial DNA polymerase gamma catalytic subunit gene (POLG1) have
proven to be a common and important underlying cause of many severe
neurological disorders with surprisingly diverse clinical manifestations.
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Review of the literature
1. Mitochondria
1.1 Origin of mitochondria
Mitochondria are thought to have been derived from endosymbiotic prokaryotes
about 1.5 billion years ago as a consequence of symbiosis of oxidative bacteria
and glycolytic proto-eukaryotic cells.1 Most likely, the common ancestor was
related to -proteobacteria, a group of intracellular parasites2. Studies on
prokaryotic and diverse mitochondrial genomes suggest that the bacterial genome
that resembles mtDNA most closely is that of the intracellular parasite Rickettsia
prowazekii 3 which seems to be the evolutionarily closest equivalent to the
common ancestor of all existing mitochondria thus far known. Further evidence
comes from the protozoan Reclinomonas Americana.4 This bacterium-like
mitochondrial genome contains 97 genes, out of which 67 genes encode proteins
also found in all sequenced mitochondrial genomes. Theoretically, it could
represent one of the transitional ancestors of all known mitochondria.
1.2 Structure
The overall structure and compartmentalization of mitochondria, consisting of
inner and outer phosholipid bilayers (IM and OM, respectively), are compatible
with the bacterial origin of mitochondria (Figure 1). The inner membrane contains
cardiolipin, an unusual phospholipid, which is a characteristic component of
bacterial plasma membranes. The inner membrane is highly folded into cristae
and there is experimental evidence to suggest that cristae might form separate
discontiguous compartments.5 Most likely, the purpose of this folding is to
maximize the inner membrane area and the volume of the intermembrane space
between two membranes.
The outer membrane has a lipid composition similar to that of the cell
membrane. It contains aqueous channel-forming porins, which enable diffusion of
ions and small molecules (<5000-6000 daltons) through the membrane. OM and IM
also contain specific transport protein complexes that control nuclear encoded
protein import (TIM/TOM) and small molecule traffic permeases.6
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The inner membrane has a higher protein to phospholipid ratio than the outer
membrane, and it is practically impermeable. Only molecules such as molecular
oxygen and water can diffuse freely through IM. IM embeds the five protein
complexes I-V responsible for respiration and ATP production in a process known
as oxidative phosphorylation (OXPHOS). Furthermore, the intermembrane space
has a composition of ions and small molecules similar to that of cytosol. This
space serves as a dynamic container of potential energy pumped from the matrix
through the OXPHOS-complexes I, II and IV into the intermembrane space in the
form of protons (H+). This proton gradient between the intermembrane space and
the matrix is the ultimate driving force of ATP synthesis, being in principle
analogous to a dam and a water turbine transforming potential energy to electrical
energy.7
In the matrix, attached to the inner membrane, reside the nucleoids. These
complex inner membrane associated structures contain a few copies of
mitochondrial genomes (2-10) each, as well as proteins involved in the
maintenance of mtDNA, gene expression and protein translation.8,9 The matrix is
also the compartment where biosynthesis (amino acids, lipids, heme and steroids)
as well as catabolic reactions (Krebs cycle, -oxidation, urea cycle) take place.7
Figure 1. Schematic presentation of mitochondrial compartmentalization.The inner
membrane is highly folded (cristae), which increases its surface area and the volume of
the intermembrane space. Nucleoids containing mtDNA molecules (2-10) and replication
















The primary function of mitochondria is to convert the chemical bond energy of
fatty acids, amino acids and carbohydrates into chemical bond energy conserved
as adenosine triphosphate (ATP). Mitochondria have another important role in
controlling and mediating apoptosis. Additionally, mitochondria synthesize heme
and steroids, regulate the cellular redox state, buffer calcium, produce heat and
most likely have additional, as yet uncharacterized functions. It is therefore self-
evident that mitochondrial dysfunction has the potential to cause a wide variety of
diseases (reviewed by 10).
1.3.1 Oxidative phosphorylation
The initial steps of energy conversion by oxidative phosphorylation take place in
the cytosol. Pyruvate, catabolized from glucose is actively transported into the
mitochondrial matrix through the outer and inner membranes. In the matrix,
pyruvate dehydrogenase combines pyruvate with coenzyme A, which is fed into
the citric acid cycle (Kreb’s cycle, tricarboxylic acid cycle=TCA). This cycle creates
three molecules of NADH and one molecule of FADH2, which forward their
electrons in a series of reduction/oxidation reactions within multi-subunit
complexes I-IV by ubiquinone (from I and II to III) and cytochrome c (from III to
IV). Gradually, step by step, electrons release their energy and finally reduce
molecular oxygen into water within complex IV (Figure 2). The respiratory chain
complexes I, II and IV pump protons from the matrix into the intermembrane
space, creating an electrochemical gradient across the inner membrane. The
proton gradient formed is exploited to drive ATP synthase (complex V), which
phosphorylates ADP to ATP, hence finalizing the energy conversion process. The
overall principle of this OXPHOS system is simple: the chemical bond energy of
nutrients is converted into chemical bond energy of ATP and heat in a highly
controlled fashion. This system employs different forms of energy such as
potential (electron gradient, proton gradient) and kinetic (ATPase) in order to
make this conversion occur.  All of these different forms of energy originally come
from the energy bound in the chemical bonds of the nutrients and the net sum of
energy remains constant.7
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Figure 2. Principle of OXPHOS system consisting of five enzyme complexes CI-CV.
NADH and succinate are oxidized by the complexes I and II. Electrons (e-) are transferred
(dashed line) from the complexes I and II to III through the coenzyme Q (CoQ) and from
complex III to complex IV by cytochrome c (Cyt C) and finally to molecular oxygen (O2),
which is reduced to water (H2O). The electron transfer is coupled with proton (H+)
translocation from the matrix to the intermembrane space. It is assumed that the transport
of two electrons enables the complexes I and III each to extrude four protons, while
complex IV pumps two. The protons pumped into the intermembrane space flow back to
the matrix through complex V providing proton gradient energy to phosphorylate
adenosine triphosphate (ATP) from adenosine diphosphate (ADP) and phosphate (Pi).
1.3.2 Reactive oxygen species, ROS
Since mitochondria are the site of cellular respiration, and molecular oxygen is the
final acceptor for electrons carried through the respiratory chain, it is inevitable
that some electrons leak from the respiratory chain to partially reduce molecular
oxygen (O2), forming superoxide anion O2 . This highly reactive anion is rapidly
converted into hydrogen peroxide H2O2 by mitochondrial superoxide dismutase
(MnSOD) and further into hydroxyl radical OH- in the presence of metals such as
Fe2+/3+ (Figure 3).11
The role of oxygen radicals is controversial. On the one hand, they have been
regarded as the obligatory and toxic side product of respiration underlying
neurodegenerative diseases and ageing in general.12-16 But  there  is  also
increasing evidence that ROS formation is strictly regulated, and that these
radicals are involved in various cellular processes such as signalling and
modification of the mode of action of proteins.11,17
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Figure 3. Reactive oxygen species, ROS. Electrons leak mainly from complexes I and
III forming superoxide from molecular oxygen. Superoxide is converted to hydrogen
peroxide by superoxide dismutase (SOD). Hydrogen peroxide in turn is detoxified to
water primarily by glutathione peroxidase (GPX). In the presence of transitional metal
Fe2+/3+, hydrogen peroxide is catalyzed to hydroxyl ion (Fenton reaction).
1.3.3 Apoptosis
One of the crucial ”missions” of all proliferative cells  is their ability and ”duty” to
commit suicide, programmed cell death (PCD), in order to maintain cellular
balance in tissues or to regulate embryonic development by removing redundant
cells. One form of PCD is apoptosis, which provides defence against damaged
and therefore potentially dangerous cells, which might otherwise lead to
cancerous development. Apoptosis was originally described by Kerr and Wylie.18
Apoptosis involves interplay between several proteins, and this mechanism must
clearly be under rigorous control and regulation, both inhibitory and stimulatory.
Up to date, the nematode Caenorhabditis elegans has been an important
organism in studies of apoptosis (reviewed by 19 ).
Apoptosis is an active process, which consists of specific and sequential
morphological changes seen in dying cells, such as fragmentation of DNA,
condensing of nucleus and blebbing of cytoplasm.20 Not all  forms of  PCD share
the characteristic shapes and sequences of apoptosis, but all types of PCD are














Two distinct pathways leading to apoptosis have been characterized. The
extrinsic pathway is initiated by activation of cell membrane death receptors, for
example Tumor Necrosis Factor (TNF) or Fas receptor.21,22 The intrinsic pathway
can be triggered by various stimuli such as DNA damage, ultraviolet radiation,
chemotherapy, oxidative stress, etc. The intrinsic pathway requires disruption of
mitochondrial membranes and release of the small heme protein cytochrome c
into cytosol.   Cytochrome c is localized in the mitochondrial intermembrane space
and is an essential component of the respiratory chain carrying electrons from
complex III to complex IV (cf. Figure 2). Many proapoptotic stimuli act by releasing
cytochrome c into cytosol, where it can form a complex with other factors forming
apoptosome passing forward the death signal.23 Many factors that regulate the
release of cytochrome c, both preventative and stimulatory, act by affecting the
integrity of the mitochondrial outer membrane. This decision is affected by the
relative ratio of pro- and anti-apoptotic mediators. Other mitochondria-associated
factors include proteins such as Apoptosis Inducing Factor (AIF),  Endonuclease
G (EndoG), High-temperature requirement protein A2 (HtrA2) and Direct IAP-
Binding Protein with Low pI (DIABLO)(reviewed by 24,25).
2. mtDNA
2.1 Structure, organization and expression
Human mtDNA is a double-stranded and closed circular molecule that consists of
16569 basepairs and is about 5.2 µm long in a linearized form. Therefore, it has to
be highly condensed or supercoiled to fit inside the mitochondrion as a part of the
nucleoid structure. mtDNA encodes 13 essential protein subunits of the OXPHOS
complexes I (7 subunits), III (1 subunit), IV (3 subunits) and V (2 subunits), two
ribosomal RNAs (16S and 12S) and 22 transfer RNAs (Figures 4 and 5). The vast
majority of the mitochondrial proteins are encoded by nuclear genes, including
OXPHOS-subunits and proteins involved in the expression and maintenance of
mtDNA, as reviewed by.26,27 Twenty-eight mtDNA genes are encoded by heavy
strand genes and nine by complementary light strand genes; all mtDNA genes
lack introns.28,29 The largest non-coding region ( 1kb) is the displacement loop (D-
loop) involved in the regulation of replication and gene expression.
MtDNA is localized in the inner membrane associated nucleoprotein structures
known as nucleoids (2-10 copies each, reviewed by 30,31), which also comprise
such proteins as DNA polymerase gamma catalytic -subunit (pol ), DNA
polymerase gamma accessory -subunit (pol ), TWINKLE DNA helicase32,
single strand DNA-binding protein mtSSBP 33 and major DNA packaging protein
TFAM.34,35 Thus far, TFAM seems to be the most abundant nucleoid protein,
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being present as about 1000 copies per mtDNA molecule.36 Studies with Xenopus
laevis oocytes have revealed putative nucleoid-associated proteins, such as
adenine nucleotide translocator (ANT) and prohibitin.37 Mammalian cells may
contain thousands of copies of mitochondrial DNA organized in several hundred
nucleoids.38,39 Nucleoids form the basic units redistributing during mitochondrial
fission and fusion8 and there is evidence that they are also connected with the
cytoskeleton.38 The mtDNA molecules in nucleoids are engaged in a variety of
processes, including replication and transcription. However, the detailed
organization and molecular composition of the nucleoid in higher organisms is not
known.
Figure 4. Organization of human mitochondrial genome. Boxed abbreviations indicate
the regulatory sites for transcription (HSP=heavy strand promoter, LSP=light strand
promoter,TERM=termination site) and origins of replication (OH and OL).One letter
symbols indicate the positions of tRNA genes (solid grey) and black regions of the heavy
strand indicate position of ribosomal RNA genes 12S and 16S. Remaining genes encode
13 of the OXPHOS subunits (underlined). The major noncoding region is the
displacement loop, i.e. D-LOOP. Modified from the thesis of Anu Suomalainen: Mutations








Figure 5. Only minority of the mitochondrial proteins are encoded by
mtDNA.The mitochondrial genome encodes 13 out of ~87 subunits of the oxidative
phosphorylation system (OXPHOS) as well as the tRNAs and rRNAs for
mitochondrial translational machinery. The subunits encoded by nuclear or
mitochondrial genomes are indicated. The other mitochondrial proteins are coded
by nuclear genes and imported through the membrane embedded protein
complexes TIM and TOM, i.e. the translocase complexes of the inner/outer
mitochondrial membranes (reviewed by6).
2.2 mtDNA gene expression
Mitochondrial genes are expressed as polycistronic messenger RNA’s (mRNA)
from two promoters (HSP, heavy strand promoter and LSP, light strand promoter)
located in the D-loop.6,26,40 The minimal human mitochondrial transcription
apparatus comprises the RNA polymerase POLRMT, the transcription factor/DNA
binding protein TFAM and the two co-activator proteins TFB1 and TFB2, which
also posses rRNA methyltransferase activity, although this activity is not required
for transcriptional activation.41 42 43 In addition, the transcription termination factor
mTERF 44 controls the ratio of messenger RNA to ribosomal RNA. Two isoforms
of the human mitochondrial transcription specificity factors TFB1 and TFB2 have
been identified.42,43 Both have been demonstrated to interact with TFAM and the














mtDNA 22 tRNA’s2 rRNA’s
>1400 nuclear encoded proteins
Human Mitochondrial Protein Database (HMPDb)
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human TFB1 and TFB2 is regulated by two nuclear respiratory factors, NRF-1 and
NRF-2, as well as PGC-1 family coactivators, all of which are essential factors for
mitochondrial biogenesis.45
Nuclear encoded protein TFAM was originally described as a mitochondrial
transcription factor also involved in mtDNA maintenance.46,47 TFAM binds
conserved regulatory sequences (enhancer) within the D-loop of mtDNA and
recruits other replication factors to the D-loop.48 Because the normal TFAM
cellular levels significantly exceed those needed for transcription, TFAM has been
postulated to act in a histone-like fashion, providing protection to the mitochondrial
genome excluding the D-loop region.36,37,48,49
2.3 Dysfunction leads to mitochondrial disease
In 1962 Rolf Luft described a patient with severe hypermetabolism and abnormal
mitochondria in the skeletal muscle.50 This was the first known diagnosed case of
mitochondrial disease. One year later the mitochondrial genome was found.51,52
Since then, a large number of patients have been described to have evident
dysfunction  of the respiratory chain. Another milestone in the history of
mitochondrial disorders was the sequencing of mtDNA28, but it took seven years
before the first pathological mtDNA mutations were discovered in 1988.53,54
Today, more than a hundred distinct mutations of mtDNA have been reported to
underlie different pathological states.
Mitochondrial genetic diseases are often characterized by alterations in the
mitochondrial genome, such as point mutations, deletions, rearrangements or
depletion of mitochondrial DNA (mtDNA). These mutations are either primary or
secondary, the latter being due to primary mutations in nuclear-encoded
mitochondrial genes such as the catalytic subunit of DNA polymerase gamma
(POLG1), which lead to secondary mutations in mtDNA and OXPHOS dysfunction
(Figures 6 and 7). The “normal” mutation rate of the mitochondrial genome is 10-
20 times greater than that of nuclear DNA, and mtDNA is more prone to oxidative
damage than is nuclear DNA.55 Mutations in human mtDNA can cause premature
aging and severe neuromuscular pathologies which are maternally or autosomally
inherited (reviewed by 56-58).
Mitochondrial diseases cover the disorders that are caused by mutations in
either nuclear or mitochondrial genes. Mitochondrial diseases may take on unique
characteristics both because of their mode of inheritance and because
mitochondria are critical to cell function. However, the effects of mitochondrial
disease can be quite diverse. Since the distribution of defective mtDNA may vary
from organ to organ within the body, a mutation that may cause liver disease in
one person might cause a brain disorder in another (Figure 8). In addition, the
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severity of the defect may vary extensively. Some defects cause adult onset
exercise intolerance, which is a sign of myopathy. Other defects can affect
mitochondrial function more severely and cause serious multisystem
consequences with early onset.
Although mitochondrial diseases vary greatly in their presentation from person
to person, several major categories of the disease have been defined, based on
the most common symptoms and the particular mutations that tend to cause them
(see http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=OMIM )
Figure 6. Three genetic pathways can lead to OXPHOS dysfunction. A) Mutated
nuclear gene encoding a defective subunit of OXPHOS complexes or an assembly factor
or a defective component of mitochondrial translation machinery. B) Maternally inherited
mtDNA harbours a pathogenic mutation. C) Mutation of a nuclear gene encoding
defective protein involved in mtDNA maintenance leads to secondary defects in mtDNA.
What B and C have in common is that the adverse effect is caused by defective mtDNA

































Figure 7. Dysfunction of oxidative phosphorylation leads to ATP depletion and
enhanced production of reactive oxygen species (ROS). Reactive oxygen species
(ROS), or free radicals, are generated as a result of respiratory chain dysfunction (cf. Fig
3). These free radicals have at least one unpaired electron, which makes them chemically
unstable and highly reactive with other molecules. Gradually, damage accumulates due
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Figure 8. Mitochondrial disorders have many clinical manifestations with a

































2.4 Maternal inheritance of mitochondrial disease
MtDNA is inherited maternally, as compared to the nuclear gene inheritance
modes, namely recessive and dominant autosomal or X-linked inheritance.59
Nuclear genes have two copies per cell, whereas haploid germ cells have only
one copy. One copy is inherited from the father and the other from the mother.
Mitochondria, however, contain their own DNA and have variable numbers of
copies, depending on the cell types and their energy demands. MtDNA is strictly
inherited from the mother and transmitted further by the female germline.
Normally, these mtDNA copies are identical, a situation called “homoplasmy”. If
two different populations exist, the situation is called “heteroplasmy”.53 The two
mtDNA pools segregate into daughter cells upon cell division, and the segregation
pattern determines the ratio of mutant to wild-type mtDNA in a given tissue or
cells. A situation where more than two distinct mtDNA sequences occupy the
mitochondria is called “pleioplasmy”. 60
In a situation where the mother is a carrier of a heteroplasmic mtDNA pool,
distinct cells and tissues may have different ratios of mutant to wild-type mtDNAs.
This also applies to the ovarian precursor cells (primordial germ cells). If these
precursor cells have a heteroplasmy ratio of 50/50%, for example, then the
individual mature ovum can have a distinct ratio of mutant to wild-type mtDNA due
to reduction of mtDNA amount and random distribution of mutant and wildtype
mtDNAs after meiosis (Figure 9).61 When the mature oocyte is fertilized, the
outcome regarding disease depends partly on the initial ratio of mutant versus
normal mtDNA in the individual oocyte. If there are enough cells in individual
tissues or specific organs, which have reached the critical amount of mutated
mtDNA, it would most likely lead to an impaired OXPHOS-system causing clinical
manifestation ( for a review see 62).
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Figure 9.  Concepts of maternal inheritance, mitochondrial heteroplasmy,
genetic bottleneck and threshold effect. Heteroplasmy= more than one
genetically different copy of mtDNA present in cells or tissues. Bottleneck= amount
of mtDNA decreases during maturation of ovum, this can change heteroplasmic
ratios dramatically or even lead to homoplasmy, when there is only one mtDNA
species. Threshold effect = amount of mutant mtDNA exeeds levels where
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3. Gene expression of nuclear encoded mitochondrial proteins
The nuclear respiratory factors 1 and 2 (NRF-1/2) are transcription factors that
regulate the expression of the nuclear-encoded mitochondrial proteins needed for
oxidative phosphorylation, components of the mitochondrial transcription
machinery and the protein import complex. The binding of NRF-1 to genomic DNA
is regulated by the ATP requirements of the cell. Promoters of the human genes
for the pol  catalytic subunit, the accessory subunit pol  and the mitochondrial
transcription factor (mtTFA) contain consensus-binding motifs for NRF-1. NRF-2
has been shown to activate at least cytochrome oxidase subunit IV expression
although it might be involved in expression of multiple respiratory genes, as
reviewed by 63.
In 1999, Wu et al. showed that PGC-1 64, a cold-inducible coactivator of
nuclear receptors, stimulated mitochondrial biogenesis and respiration in muscle
cells through an induction of uncoupling protein 2 (UCP-2) and through regulation
of the nuclear respiratory factors (NRFs). PGC-1stimulates induction of NRF-1
and NRF-2 gene expression; in addition, they showed that PGC-1 binds to and
coactivates the transcriptional function of NRF-1 on the promoter for mitochondrial
transcription factor A. (reviewed by 65).
4. mtDNA replication
The basic processes of mitochondrial DNA replication were initially elucidated with
studies on budding yeast. Yeast mtDNA is ~80 kb, i.e. almost five times the size
of human mtDNA, and it contains bidirectional origins of replication (ori/rep
sequences numbered 1-8). This mechanism is similar to that of mtDNA replication
in vertebrates and has been recently reviewed by 66.
Currently, the replication of mtDNA is not fully understood, and there are two
major theories (the Clayton and Holt-Jacobs models) of how this replication is
accomplished. 40,67-74 Progress has been made by identifying a growing list of
proteins involved in the replication and by reconstitution of an in vitro
mitochondrial replisome capable of synthetizing single-strand DNA, which is close
to the full size of mtDNA. 75 This minimal replisome consists of pol , pol  and
TWINKLE helicase. The addition of mitochondrial single-stranded DNA-binding
(mtSSB) protein enhances processivity, 5’-3’ DNA helicase TWINKLE 32 unwinds
the DNA, and pol  itself catalyses mtDNA replication.76 In vivo the situtation is
more complex and highly regulated, requiring additional accessory proteins and
synthesis and processing of RNA,77 and this will be discussed in more detail
below.
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4.1 Mechanisms of DNA replication in mitochondria
4.1.1 Clayton-model
The first model of mammalian mtDNA replication was reported in 1982.67
According to this model, the replication of mtDNA takes place  in a unidirectional
and asymmetric fashion in mouse L-cells (Mouse embryo fibroblast, Moloney
Sarcoma Virus transformed).26,67,78 This model has two characteristic features.
Firstly,  mtDNA  has  two  distinct  origins  of  replication:  OH in the D-loop and OL
approximately two thirds downstream (cf. Figure 4).79,80  Secondly, transcription
initiates replication from OH displacing the H-strand and synthesizing a new one
until OL  is reached. So far, two thirds of the new H-strand has been synthesized.
At this point, displacement of the H-strand exposes the OL  , from which the
synthesis of the lagging strand initiates.In this model the primer for the initiation of
mtDNA replication at OH  is  believed to be generated by processing the transcript
starting at LSP.26,81
4.1.2 Holt-Jacobs model
Recently, the Clayton model was challenged by a more conventional model based
on studies of mtDNA replication using two-dimensional gel electrophoresis70,82,83.
This model presumes that replication proceeds in the presence of conventional
duplex replication intermediates indicating symmetric, semidiscontinuous DNA
replication with coupled leading and lagging strand DNA synthesis. Initially,
replication was believed to initiate at or near OH, proceeding unidirectionally
around mtDNA and suggesting coexistence of both asynchronous and strand-
coupled modes of mtDNA replication.70 Later, this model was revised by the same
authors based on the assumption that mammalian mtDNA replication proceeds
mainly, if not exclusively, by a strand-coupled mechanism.82,83 In addition,
replication was shown to initiate at multiple sites along mtDNA, proceeding
bidirectionally. The most recent findings indicate that the mtDNA replication in
verterbrates comprises elements called RITOLS (Ribonucleotide Incorporation
ThroughOut the Lagging Strand). These are short stretches of ribonucleotides
found in the lagging strand, indicating that there might be uncharacterized
primase activity, or alternatively, these are preformed oligoRNAs hybridized to the
L-strand. The initiation of the replication of the H-strand from RITOLS seems to
occur in the non-coding region and is unidirectional.74
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4.1.3 In vitro replisome
Korhonen et al.75 provided novel insight into the biochemical aspects of mtDNA
replication reconstituting a minimal mtDNA replisome. The replisome contained
recombinant pol  and pol -  (both catalytic and accessory subunits), TWINKLE
and mtSSBP. The combination of three proteins, pol  - , pol  and TWINKLE,
demonstrated efficient synthesis of single-stranded DNA approximately 2000 nt in
length, using double-stranded minicircle DNA as a template. Addition of mtSSB to
the complex permitted synthesis of single-stranded DNA products more than 15
000 nt in length, a size similar to the mammalian mitochondrial genome.75,76
5. DNA polymerase gamma, polG holoenzyme
So far, altogether 16 mammalian DNA polymerases have been identified. These
polymerases are essential in maintaining genetic information through faithful
replication and repair. Only one of these polymerases is involved in maintaining
the mitochondrial genome (mtDNA), namely DNA polymerase gamma
holoenzyme (polG), which is encoded by the nuclear genes (POLG1 and POLG2)
and imported into mitochondria. It represents only about 2% of total cellular
polymerase activity. In mammals, including humans, it has a C-terminal DNA-
polymerizing activity (pol-domain) and N-terminal proofreading activity (exo-
domain). These domains are separated by a spacer or linker region, which is
thought to have a role in DNA binding and interaction with the processivity subunit
(pol ) of the holoenzyme (Figure 10). Pol  shows some exceptional
characteristics, which differentiate it from the other mammalian polymerases.
These include reverse transcriptase activity, sensitivity to N-ethylmaleimide
(NEM), capability to incorporate dideoxy-NTPs, resistance to aphidicolin and
stimulation by salt.84,85 Dysfunction of pol  has turned out to be an important
and common cause of neurodegenerative diseases. When mutated, it causes
secondary defects on mtDNA, such as deletions, point mutations and depletion,
which lead to defective or reduced synthesis of mtDNA-encoded components of
the respiratory chain. In addition to polG, other proteins known to be involved in
mtDNA replication and maintenance are briefly reviewed.
5.1 Discovery and characterization of polG
In 1970, the first reports 86,87 describing RNA-dependent DNA polymerase activity
were published. Five years later, this new polymerase was designated as pol
(polG), 88  although its cellular function was unclear.
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In 1977, polG was localized to the mitochondrial compartment,89 and evidence
supporting the functional role of polG in mitochondria was obtained two years later
in a study of isolated brain synaptosomes.90 The first evidence of human
mitochondrial DNA polymerase gamma was reported in 1987.91 With the aid of
homologous yeast sequences, human and fruit fly genes were cloned.92
The human heterotrimeric holoenzyme (195 kD) is composed of two subunits
of accessory subunits (pol )84 and one subunit of catalytic pol  which
possesses DNA polymerase,84 3’-5’ exonuclease 93 and 5’dRP lyase activities.94
Figure 10. Linear organization of catalytic subunit of DNA polymerase gamma.
The exonuclease domain (striped horizontal bar) contains three conserved motifs
(vertical black bars) as does the polymerase domain (horizontal black bar). The
spacer domain consists of four moderately conserved blocks, 1-4 (white horizontal
bars) and has functions in template DNA binding, positioning and interaction with an
accessory subunit. In addition, the N-terminus has short polyglutamine tract most
commonly thirteen glutamine residues long. The function of the polyglutamine tract
is not known. The most common polyglutamine tract is encoded by ten cag-triplets
followed by one caa- and two cag-triplets. The second most common allele has
eleven cag-triplets, one caa- and two cag-triplets.
Several groups then reported an additional polypeptide that associates with
the catalytic subunit. 95-98 The gene encoding this peptide was first identified in the
fruit fly, and a database search revealed a partial human homolog.99 Full-length
human cDNA was cloned, expressed and purified a few years later.93 This protein
has been nominated as pol , and it is the accessory subunit encoded by the
nuclear gene, POLG2. The human accessory subunit pol  is required for highly
processive DNA synthesis.93,100,101 The accessory subunit forms a high-affinity,
salt-stable complex with pol . Reconstitution of the human complex with
recombinant subunits restores salt tolerance, stimulates polymerase and
exonuclease activities, and increases the processivity of the enzyme by several
100-fold. pol  also binds double-stranded DNA with moderate strength and
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specificity. Amino acid alignment of the Drosophila melanogaster, Xenopus laevis,
and human accessory subunits revealed significant homology to the class II
aminoacyl-tRNA synthetases,102,103 although the ATP binding and the anticodon-
binding sites are impaired.104
Mitochondrial DNA accounts for approximately 1% of total cellular DNA, and
pol  activity comprises only 1-5% of total cellular DNA polymerase activity. pol
belongs to the family A polymerases,105 which includes the Klenow fragment of
E.coli, Taq polymerase and bacteriophage T7 DNA polymerases, to mention just
a few.
POLG1 is expressed and translated in cultured human cell lines that either
contain or lack mitochondrial DNA, indicating that the pol  is stable in the
absence of mitochondrial DNA in vivo.92
5.2 Molecular structure of the pol  catalytic subunit
So far, the three-dimensional structure of pol  has not been solved, although
many 3-D structures of prokaryotic polymerases belonging to the same
polymerase A family have been resolved (reviewed by 106 ) According to these
results, the predicted structure of the pol  polymerase domain shows well-
defined fingers, thumb, and palm subdomains. This model has provided structural
insights into the function of many of the conserved amino acids at the active site,
which has been useful in predicting the potential effect of disease mutations.
107,108
5.3 Molecular structure of the accessory subunit, pol
A three-dimensional model of the C-terminal region of pol  was developed in
1999, 103 and the three-dimensional structure of the mouse accessory subunit was
determined two years later. This showed that the subunit crystallized as a
dimer.104 pol  seems to show some structural similarities to the N-terminal
domain of the subunit of the complex in E.coli DNA polymerase III and E. coli
thioredoxin,103 and the overall crystal structure is remarkably similar to that of
glycyl-tRNA synthetase but the functional sites of aminoacyl-tRNA synthetases
are not conserved in the pol  accessory subunit.104
Studies with deletion mutants have shown that interaction with the catalytic
subunit occurs via a highly conserved C-terminal domain.100 Furthermore,
physical studies have shown that a pol  deletion mutant lacking the N-terminal
two-helix bundle cannot dimerize.109 In addition, the accessory subunit was shown
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to bind the catalytic subunit as a homodimer forming a heterotrimeric holoenzyme.
Several studies suggest that the interacting region in the catalytic subdomain is
located in the early spacer domain.110-112 Studies conducted in vitro show that
pol  stimulates polymerase and exonuclease activities and increases the
processivity of pol  in different species. 93,101,102,113
5.4 Enzymatic activities of pol
5.4.1 Polymerase activity
In addition to natural templates, human pol  can utilize a wide variety of DNA
substrates, including activated DNA, singly primed M13 DNA and several
homopolymers such as poly(dA)•oligo(dT) and poly(dC)•oligo(dG). pol  also
possesses reverse transcriptase activity, which permits differentiation of this
activity from most other cellular DNA polymerases by assay on
poly(rA)•oligo(dT).84,114 In addition to DNA polymerizing activity, copurification of
3’-5’exonuclease activity has been shown in various species.95,97,98,115-119
The catalytic rate of reverse transcription is higher for pol  than for HIV-1
reverse transcriptase, and there is also evidence of proofreading activity with the
RNA template. This variety of templates might indicate that pol  as the sole
mitochondrial DNA polymerase has additional and unknown roles in nucleic acid
processing. pol  is active between pH values of 7.5 and 9.5, and the enzyme
also requires a divalent metal cation. Mn2+cations are preferred on DNA
templates, whereas Mn2+ are required for efficient utilization of ribopolymeric
templates.84 120
5.4.2  3'- 5' Exonuclease Activity
pol -associated exonuclease activity was first characterized in several
species.97,116-118 Using a yeast homolog of pol , MIP1, three exonuclease motifs
were identified105 as having significant homology with other family A polymerase
exonuclease motifs.  Mutagenization of the yeast exo-motifs 1, 2 and 3 retained
the polymerase activity, but the strains exhibited a several 100-fold increase in the
frequency of mutations of mtDNA relative to the wild-type enzyme with its intact,
mismatch-specific 3'-5' exonuclease activity.121 Subsequently, the intrinsic 3'-5'
exonuclease activity of pol  was also shown in the human catalytic subunit and
reconstituted forms of the human holoenzyme.84,93,101,122 Exonuclease activity also
has a broad pH optimum, requires a divalent metal cation and is stimulated by
moderate to high concentrations of NaCl. The exonuclease shows preference for
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3'-terminal mispairs in double-stranded DNA and degrades efficiently single-
stranded DNA. pol  has a high mismatch specificity ranging from 5- to 34-fold,
depending on the DNA substrate and the specific nucleotides that make up the
mispair.84,85,117,118,123 pol  can replicate DNA accurately with error frequencies of
less than 3.8x10-6/nt, 97,116 indicating that the exonuclease contributes to
replication fidelity. All family A DNA polymerases with intrinsic exonuclease
activity contain conserved residues in their exonuclease active sites, which
coordinate the two metal ions involved in catalysis.124 Substitution of these
residues in human pol  (D198A and Q200A) with alanine in the ExoI motif
eliminates the detectable 3'-5' exonuclease function in vitro. 84 Comparison of the
base substitution errors of mutant (exo-)  and  wild-type  pol  shows  ~20-fold
higher fidelity in the wild-type.125
Expression studies with human cultured cells show accumulation of point
mutations when exo-deficient pol  is introduced to cells.126 Several mutations
associated with PEO or Alpers syndrome have been found in the exonuclease
domain, but none of them are located within the conserved exo-motifs.127-138 All
these mutations are found as compound heterozygotes and mostly inherited as a
recessive trait.
The catalytic subunit itself has high base substitution fidelity resulting from high
nucleotide selectivity and exonucleolytic proofreading.125 However, when copying
homopolymeric sequences longer than four nucleotides, pol  has lower
frameshift fidelity, suggesting that homopolymeric runs in mtDNA may be
especially sensitive to frameshift mutations.
5.4.3  5’ dRP-lyase activity of pol
dRP-lyase activity, which catalyses the cleavage of the 5’-terminal dRP sugar
residue from apurinic/apyrimidinic sites, was first found in Xenopus laevis.139,140
The authors also demonstrated that the dRP-lyase reaction proceeds via the
formation of a covalent enzyme•DNA complex that is converted into an
enzyme•dRP intermediate. In base excision repair pathways, the damaged base
is recognized and removed by DNA glycosylase and AP endonuclease activities.
dRP lyase activity allows pol  to remove the dRP residue and to fill the resulting
single-nucleotide gap, thereby generating a substrate for DNA ligase.94 The
accessory subunit can increase the efficiency of this reaction by increasing the
lyase activity and the ability of the enzyme to locate the damage site on DNA,
presumably by enhancing DNA binding.141
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5.4.4 polG in mitochondrial DNA repair
In addition to damage by reactive oxygen species, mtDNA is also damaged by
exposure to radiation and chemicals. Repair of the damage to mtDNA is
necessary to avoid the accumulation of point mutations and/or deletions. Certain
types of DNA damage can be efficiently repaired in mitochondria. As the only
DNA polymerase present in mitochondria, polG is involved in these repair
processes such as base excision repair (BER).94,142,143
5.5 Proteins with putative interactions with polG
5.5.1 TWINKLE, mitochondrial 5’-3’ DNA helicase
In 2001, Spelbrink et al. 32 reported a nuclear gene (PEO1), which encodes a
mitochondrial DNA helicase TWINKLE. The protein is similar to bacteriophage T7
gp4 protein, which has N-terminal primase activity and C-terminal DNA helicase
activity and is required at phage replication fork.32 The authors reported also four
ethnically distinct autosomal dominant PEO-families carrying mutations in this
gene.  The authors found that C. elegans and Drosophila have similar proteins,
also related to T7 gp4. Although homologous to T7 primase-helicase, TWINKLE
has not been shown to harbour primase activity. Instead, it has been shown to
localize in mitochondrial nucleoids and cells overexpressing twinkle had an
increased mtDNA helicase activity. 8
TWINKLE itself has been shown to unwind only short stretches (<20 bp) of
dsDNA in the 5'-3' direction.144 polG holoenzyme itself is unable to use dsDNA as
a template, however, when the polG and TWINKLE are combined, they form a
processive replication machinery, a replisome, which can utilize dsDNA as
template to synthesize ssDNA molecules of about 2 kb. Addition of the
mitochondrial single-stranded DNA-binding protein (mtSSBP) stimulates the
reaction, generating DNA products of about 16 kb, the size of the mammalian
mtDNA molecule.75
Pol  and its dsDNA-binding activity are required for the function of the
mitochondrial DNA replisome. The dsDNA-binding activity of accessory subunit is
not required to stimulate the DNA synthesis rate or the processivity of the pol
but is needed for functional interactions between the polymerase gamma
holoenzyme and TWINKLE. There is no proof for physical interactions between
the components of the mtDNA replisome, but functional interaction may explain
the dependence on TWINKLE and the polG holoenzyme for DNA synthesis.76
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5.5.2 Single strand binding protein, mtSSBP
In 1995, Tiranti et al.145 reported that the gene encoding mitochondrial single-
stranded DNA-binding protein (mtSSBP) is a housekeeping gene involved in
mitochondrial biogenesis. mtSSBP is a small protein (132-amino acids) that acts
as a homotetramer to stabilize the displaced single strand DNA during mtDNA
replication. The most likely role of mtSSBP is the prevention of the formation of
secondary ssDNA structures, which could stop the polG, causing replication
stalling.
Farr et al. have shown that functional interaction of mtSSBP and polG enhance
the overall activity of polG in Drosophila embryos by increasing primer recognition
and stimulating the initiation of DNA strand elongation.146 Later they showed that
DNA-binding mutants of mtSSBP are defective in stimulation of DNA synthesis by
polG. Knock-down of mtSSBP reduced the expression level of the gene to less
than 5%, resulting in mtDNA depletion and growth defects in Schneider cells.
Overexpression of mtSSBP restored the cell growth and mtDNA copy number. 147
Korhonen et al.75 have also shown the stimulatory effect of mtSSBP to mtDNA
replication with human orthologs in vitro, as mentioned earlier.
6. Human disorders associated with defective pol
POLG1, is one of the nuclear genes that is associated with mitochondrial DNA
depletion or deletion disorders when mutated. Dysfunction of  mitochondrial DNA
polymerase gamma has been associated with disorders such as progressive
external ophthalmoplegia (PEO),138 Alpers syndrome,148 mitochondrial
neurogastrointestinal encephalomyopathy (MNGIE)149 or sensory ataxic
neuropathy, dysarthria and ophthalmoparesis (SANDO).132 Also, polyglutamine
tract variants in the N-terminus of pol  have been implicated in male infertility in
some instances, 150 although several reports have failed to replicate that
association.151,152 Since 2001 there are several publications reporting over 80
distinct POLG1 mutations associated with diverse clinical manifestations (Figure
11). 111,127-134,136,138,148,149,153-173
6.1 Progressive external ophthalmoplegia, PEO
In 1989 multiple large-scale deletions of mtDNA isolated from muscle biopsies
were demonstrated in Italian families with the heritable autosomal dominant form
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of PEO (adPEO) by Zeviani and colleagues.174  PEO usually has late onset
(between 18 and 40 years of age) with bilateral ptosis and progressive weakening
of the external eye muscles, resulting in blepharoptosis and ophthalmoparesis,
proximal muscle weakness, wasting and exercise intolerance. Frequent additional
features include cataracts, hypogonadism, dysphagia and hearing loss.175-177 The
skeletal muscles of PEO patients contained ragged-red fibers and showed
impaired activity of respiratory chain enzymes. In 1992 Suomalainen et al.178
reported an adPEO patient with a multisystemic disorder in which one of the major
clinical symptom was depression. They also found that the patient had significant
amounts of deleted mtDNA species in skeletal muscles, brain and heart.178,179
Both autosomal dominant and usually more severe autosomal recessive
inheritance can occur, depending on the causative mutation and what gene is
affected.
Van Goethem et al.138 identified three Belgian families with PEO and multiple
mtDNA deletions. The diagnosis was based on clinical symptoms of PEO and
muscle weakness, the presence of ragged-red fibers and multiple mtDNA
deletions in muscle biopsies. Electron microscopy showed subsarcolemmal
accumulation of abnormally structured mitochondria with paracrystalline
inclusions. The inheritance pattern in one family was autosomal dominant,
whereas the other two families likely had autosomal recessive inheritance. In
2001, the first report was published describing the same families in which PEO
cosegregated with POLG1 mutations.138  In addition to POLG1 three genes have
been associated with chronic PEO, namely ANT1180, PEO132 and POLG2181
6.2 Alpers syndrome
Bernard Alpers  described in 1931the neuropathology and clinical features of a 4-
month-old girl with a one month illness characterized by intractable generalized
seizures.182 He termed the disorder 'diffuse progressive degeneration of the gray
matter of the cerebrum’. Alpers syndrome is usually characterized by
psychomotor retardation, intractable epilepsy and liver failure in infants and young
children. Definitive diagnosis is confirmed by postmortem examination, showing
typical morphological changes of the brain and liver, such as spongiosis, neuronal
loss, and astrocytosis, which progresses down through the cortical layers,
hepatocyte loss, bile duct proliferation, fibrosis, and often cirrhosis.183 The illness
usually begins in early life with convulsions. A progressive neurologic disorder
characterized by spasticity, myoclonus and cognitive decline ensues. Status
epilepticus is often the terminal development.
In 2004, the first report of POLG1 mutations underlying Alpers syndrome was
published.148 The authors reported an Alpers patient with reduced electron
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transport chain function, dicarboxylic aciduria, fulminant hepatic failure, refractory
epilepsy and lactic acidosis which resulted in death at 42 months. Sequencing
revealed that the patient was compound heterozygous, predicting Q873X and
A467T amino acid substitutions.167 Since then, reports have been published of
several other mutations found in POLG1 in 20 independent
pedigrees.129,134,156,164,168,184  At least 16 mutations associate with Alpers
syndrome. In all cases, the POLG1 mutations found in Alpers patients are
recessive. Many of these mutations also exist in PEO with recessive mode of
inheritance.
6.3 Sensory ataxic neuropathy, dysarthria and ophthalmoparesis,
SANDO
SANDO is a clinically heterogeneous systemic disorder with variable features
resulting from mitochondrial dysfunction. It shares clinical characteristics with
autosomal recessive progressive external ophthalmoplegia and mitochondrial
neurogastrointestinal encephalopathy syndrome.185
Van Goethem et al. (2003) reported a man with SANDO having disturbance of
balance, which progressed slowly during the third decade and became disabling
with frequent falls.132 At the age of 39, he presented with moderately severe
external ophthalmoparesis, mild dysarthria and ataxic gait without other muscle
weakness. The patient showed thalamic lesions on neuroimaging. The patient's
parents, both 70 years of age, were clinically normal, as was his only brother.
Sequence analysis of patients POLG1 revealed two pathogenic mutations
predicting amino acid substitutions A467T and R627W.
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Figure 11. Positions of pol  substitutions along the primary sequence of
protein. Arrows below the linear structure of pol  indicate the positions of
missense substitutions associated with different disorders. The arrows above
indicate the positions of the amino acids, which have been reported to harbour two
different substitutions: R227W or P, R232G or H, R309L or H, R627W or Q, R807P
or C, A957P or S, R1047Q or W and R1096C or H. The bold amino acid symbols
indicate dominant mutations.The R627Q substitution has been also found in
recessive MELAS. Dominant mutations are mainly clustered within the polymerase
domain (black horizontal bar) and recessive ataxias always have at least one
mutation within the spacer area. Grey box indicates the R627Q or R627W
substitution, which has been shown to act in recessive (MELAS/Ataxia)) and
dominant (Ataxia) manner (see http://dir-apps.niehs.nih.gov/polg/, and references
therein). Striped horizontal bar indicates the location of exo-domain.
7. Mouse models of exonuclease or polymerase defective pol
Thus far there have been reports of mouse models expressing defective pol
either ubiquitously or in targeted manner. Both homo- and heterozygous mice
have been used in these studies.
Substitution of a highly conserved aspartate residue with alanine in the second
exonuclease motif (D257A) produced homozygous knock-in mice expressing a
exonuclease-deficient form of the catalytic subunit of pol .186  These knock-in
mutator mice developed a mtDNA mutator phenotype with up to a 5-fold increase
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deletions. The increase in somatic mtDNA mutations was associated with a
reduced life span and premature aging, indicating that an increase in mtDNA
mutations contributes to the aging process.
Study of a similar exonuclease-deficient knock-in mouse showed that the
increase in mtDNA mutations induces apoptosis but is not associated with
increased production of reactive oxygen species.187 With more sensitive methods
Vermulst et al. 188 claimed that the mutation frequency in mutator mouse
mitochondria was more than ten times lower than was reported earlier. They
detected an 11-fold increase in mitochondrial point mutations with age and that
the mutator mice were able to sustain a 500-fold higher mutation burden than
normal mice, without any obvious features of rapidly accelerated aging, they
suggested that mitochondrial mutations do not limit the lifespan of wild-type
mice.188 Yamasoba et al. 2006 189 studied the role of accumulation of mtDNA
mutations in the development of age-related hearing loss using heterozygous
mutator mouse, which showed accelerated aging primarily due to increased
apoptosis. Mice had moderate hearing loss and degeneration of the hair cells,
spiral ganglion cells and stria vascularis by 9 month of age, while wild-type
animals did not. They claimed that decreased energy metabolism due to
accumulation of mtDNA mutations/deletions and decline of respiratory chain
function play an important role in the manifestation of AHL.
In 2007, Lewis et al.190 expressed mutated human POLG1 in murine heart.
The mutation predicts amino acid substitution from tyrosine to cysteine at the
position 955 (Y955C) and it is the most common mutation found in adPEO. In this
study cardiac targeting of Y955C-pol  caused cardiomyopathy, mitochondrial
oxidative stress, premature death and mtDNA depletion in the hearts of
heterozygous mice.
Accumulation of mtDNA deletions and mitochondrial dysfunction in the brain
has been hypothesized to cause bipolar disorders, since many PEO-patients have
similar problems.191 Heterozygous mice carrying a mutation in the first
exonuclease motif of pol  (D181A) showed altered diurnal activity rhythm and
periodic activity change associated with the estrous cycle. The phenotype was
worsened by administration of a tricyclic antidepressant, but improved after lithium
treatment.192
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8. Biochemical characterization of pathogenic POLG1
polymerase domain substitutions
Most of the dominant POLG1 mutations responsible for developing PEO-disease
have been mapped to the polymerase domain of pol .193 Graziewicz et al. 2004
studied four pathogenic amino acid substitutions, G923D, R943H, Y955C, and
A957S, which were previously shown to associate with the dominant form of PEO.
108 Exonuclease deficient double mutant of pol  with these substitutions were
characterized biochemically. Two of the substitutions, R943H and Y955C, change
side chains that interact with the incoming dNTPs.  Proteins carrying these
substitutions retain less than 1% of the wild-type polymerase activity and display a
severe decrease in processivity. The significant stalling of DNA synthesis and the
low catalytic activities of both enzymes are the two most likely causes of the
severe clinical presentation in R943H and Y955C heterozygotes. The substitution
of Y955 to cysteine also increases nucleotide misinsertion replication errors 10- to
100-fold in the absence of exonucleolytic proofreading.194 The G923D and A957S
recombinant forms of pol  showed less than 30% of the “wild-type” (exo-)
polymerase activity. This is consistent with the milder clinical manifestations of
PEO patients carrying these mutations. Because both copies of POLG1 are
expressed, autosomal dominant mutations are thought to produce proteins that
compete with the wild-type pol  in a dominant negative manner.  In addition a
slight increase in DNA-binding efficiency was observed in three of the four pol
variants: G923D, R943H and A957S.
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Aims of the study
In 2001, Van Goethem et al.138 reported three PEO families carrying either
recessive or dominant mutations in the POLG1 gene. Shortly after that, Lamantea
et al.128,130 found novel POLG1 mutations in several Italian PEO families. At that
time already, it was obvious that mutations in the POLG1 gene could cause either
recessive or dominant diseases with interfamilial phenotype variability. This
prompted us to characterize the role of POLG1 in different neurological diseases.
The specific aims of the study were as follows:
1. To study the role of POLG1 mutations in patients with known
mitochondrial disorders.
2. To identify new disease entities caused by POLG1 mutations.
3. To develop and set up diagnostic POLG1 routine analysis for clinical
purposes.
4. To study the biochemical consequences of disease mutations in vitro.
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Materials and methods
1. Patients, control individuals, cell cultures, biopsies and autopsies.
All patient samples were taken with oral or written informed consent. The studies
were approved by ethical committees of Helsinki University Central Hospital and
collaboratory institutes. The study material included:
Study I: Seven families (two Finnish, one British and four Swedish)
with progressive external ophthalmoplegia, parkinsonism and premature
menopause with a total of 22 patients.
Study II: 140 idiopathic Parkinson’s disease patients and their 127 spouses as
controls. In addition, the POLG1 polyglutamine tract of 585 healthy controls and
127 patients with other neuromuscular disorders were analysed.
Study III: Five European ataxia families (one British, two Finnish and two Belgian)
with alltogether eight patients. In addition, 168 Belgian and 70 Finnish controls
were analysed
Study IV: One Austrian family with PEO/ataxia and neuropathy. Alltogether ten
family members were analysed.
Primary cell lines (IV)
Lymphocytes were isolated from peripheral venous blood with heparin or EDTA
as anticoagulant, using LymphoprepTM Tubes (Nycomed Dharma As) according
to the manufacturer’s instructions and immortalized with the Epstein–Barr virus.
The cultures were maintained in RPMI 1640 (Gibco BRL) and supplemented with
20% fetal bovine serum (Gibco BRL), 2 mM Glutamax (Gibco BRL) and penicillin–
streptomycin, respectively (Gibco BRL) at a density of 3x106 cells/ml at 37°C in
an incubator with 5% CO2.
DNA and RNA extraction (I-IV)
Total lymphocyte, muscle and lymphoblast DNA were extracted using standard
methods. Total RNA from lymphoblasts was isolated by the RNAeasy Mini Kit
(Qiagen) according to the manufacturer's instructions. Samples were treated with
RNase-free DNase (Stratagene) to avoid carry-over of the DNA template into the
reverse transcription and PCR amplification.
Sequencing of POLG1 (I-IV)
All exons were amplified by PCR: 94°C for 10 min; 35 cycles of 94°C for 1 min,
60°C for 30 s and 72°C for 1 min and final extension 72°C for 10 min using 1 U of
AmpliTaq Gold-polymerase (Roche). The intronic primers flanking all POLG1
exons were according to Van Goethem et al.138 The PCR products were checked
by agarose gel electrophoresis, purified by the QIAEX II Gel Extraction Kit
(Qiagen) and sequenced using the BigDye terminator Ready Reaction Kit v.3 on a
3100 Genetic Analyzer Automatic Sequencer (Applied Biosystems).
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Reverse transcription and polymerase chain reactions (IV)
Titan One Tube RT–PCR System (Roche) was used to amplify (see primers
below) the fragment under study. The cycling conditions were as follows: 58°C for
30 min; 94°C for 2 min; followed by 35 cycles of 94°C for 20 s, 58°C for 30 s and
68°C for 1 min and finally 68°C for 10 min. The absence of DNA carry-over was
controlled by parallel reaction without initial cDNA synthesis before the
amplification steps. RT–PCR was used together with mini-sequencing in order to
quantitate the conceivable allele specific expression bias.
Solid-phase mini-sequencing (IV)
Initial PCR amplification was done by AmpliTaq Gold-polymerase (Roche). Solid-
phase mini-sequencing was done according to standard reaction conditions. The
part of exon 7 harbouring the A467T mutation was amplified using a 5'-
biotinylated forward primer (5'-accagaactgggagcgttac-3') and an unmodified
reverse primer (5'-ctacctctctcctgagagca-3'). Detection and quantitation of the wild-
type or mutated base were done by utilizing a detection primer (5'-
cagctggcaggcatcattgg-3') and extension with a tritiated deoxy [1',2',5-3H] cytidine
5'-triphosphate and deoxy [methyl-1',2'-3H] thymidine 5'-triphosphate (Amersham
Biosciences), respectively. Incorporation of the nucleoside triphosphates was
done by a thermostable DNA polymerase from Thermus brockianus
(DynaZymeTM/II, FinnZymes).
The part of exon 23 harboring the Q1236H variant was amplified with a 5'-
biotinylated forward primer (5'-ttgaggtggcatcctaacca-3') and an unmodified
reverse primer (5'-acgggagcaaatacagagcc-3'). Detection of both variants was
done by a detection primer (5'-cagctggcaggcatcattgg-3') with tritiated deoxy [1', 2',
5-3H] cytidine 5'-triphosphate and deoxy [3H] adenosine 5'-triphosphate
(Amersham Biosciences).
mtDNA analysis (III,IV)
Long-PCR analysis was performed using DyNAzyme EXTTM polymerase
(Finnzymes) according to the supplier’s instructions for standard reaction
conditions (0–10 kb). The primers used for this assay were located at the  nt
positions 8238–8262 (forward) and 16 496–16 465 (reverse), amplifying a region
of mtDNA that often harbours multiple mtDNA deletions. The cycling conditions
were as follows: 94°C for 2 min; 35 cycles of 94°C for 15 s, 63°C for 30s, 72°C for
2 or 6 min and final extension at 72°C for 10 min. The optimal amount of template
was titrated to be 10 ng. By reducing the amount of template, we were able to
amplify deletions only from patient samples and never in age-matched controls
(muscle samples from healthy siblings of PEO patients). Two separate PCR
reactions for each sample were set up, with otherwise similar reaction conditions
but different extension times. Six minutes extension was used to visualize the 8.2
kb product from the normal mtDNA molecule, and 2 min was used to favour the
amplification of the deleted molecules. The total DNA extracted from the muscle
biopsy sample was used for Southern blot analysis as described in detail. The
DNA was restriction-digested with BamHI or PvuII restriction enzymes
(Fermentas). Both linearize mtDNA but from separate sites. The samples were
electrophoresed through a 0.8% agarose gel, and complete digestion was
confirmed in ethidium bromide staining. The DNA was transferred on a Hybond-N
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(Amersham Biosciences) nylon membrane according to standard procedures, and
the membranes were hybridized with a probe containing a cloned fragment of
mtDNA (nt 1–740) and random-labelled to a specific activity of 1x108 c.p.m. / µl,
in order to detect deleted mtDNA species. The same membrane was rehybridized
with a nuclear probe 18S rRNA, cloned in pBR322, in order to quantitate the
mtDNA signal versus genomic DNA, to detect possible mtDNA depletion. The
radioactive signal was detected by scanning PhosphorImager screens (Fuji Photo
Film Co.) with Typhoon 9400 Imager (Amersham Biosciences) and quantitated
with the ImageQuant 5.1 software (Amersham Biosciences).
.
Statistical analysis (II)
We tested the null hypothesis of independent occurrence of rare and common
repeat length classes separately in PD patients, spouse controls, patient controls
and healthy control with the Fisher’s exact test ( http://statpages.org/ctab2x2.html)
The p-value given is two-tailed.
POLG1 haplotype frequency estimation was carried out using the expectation-
maximization algorithm as implemented in the HAPLO and SNPHAP software
(http://www.gene.cimr.cam.ac.uk /clayton/ software/snphap.txt). HAPLO was used
to estimate haplotype frequencies in the PD and control groups and to calculate a
global p-value for the association with PD. SNPHAP was used to analyze the
association of individual haplotypes with PD. For this purpose, we selected amino
acid variants or non-coding SNPs with minor allele frequencies of >5%. Four
markers were included (rs223829, L752L, rs2302084, Q1236H), which were
tested under 4-locus analysis with the HAPLO program (global test). Haplotype
patterns were also analysed with the SNPHAP software application (individual
haplotype tests).
dHPLC  (I)
Automated denaturing high performance liquid chromatography instrumentation
was used (Agilent Technologies, Palo Alto, CA, USA) to search for mutations in
one patient (family K). We amplified exons according to a published protocol138
with few exceptions: the initial denaturing step was 10 min with AmpliTaq Gold
(Applied Biosystems), with a final concentration of 1 U/50 L reaction. We
obtained the optimum melting temperature for every amplicon with an algorithm.
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Results
1. POLG1 mutations in new clinical phenotypes (studies I-IV)
In study I we showed that PEO, parkinsonism and premature menopause
cosegregated with POLG1 mutations. We found three new POLG1 mutations and
one previously described mutation in seven pedigrees with progressive external
ophthalmoplegia. This prompted us to study further the role of POLG1 mutations
in Finnish sporadic idiopathic Parkinson’s disease patients. In that study (II) we
showed that rare polyglutamine tract length variants associated with idiopathic
sporadic PD.
In study III we found one previously described and one new POLG1 mutation
in patients who had ataxia with various combinations of other neurological
symptoms. This study also showed that even patients who carry the same
mutations may have very different clinical phenotypes with or without muscle
abnormalities, such as ragged-red fibers or mtDNA deletions. Another PEO/ataxia
family was analysed in study IV.
In this family two POLG1 two mutations segregated, one of them in cis with a
polymorphic coding region variant. The index patient had the most severe
phenotype carrying two mutations predicting A467T and R627Q substitutions and
one additional polymorphic change Q1236H in cis with R627Q. Both mutated
alleles were shown to cause mild or moderate clinical phenotype, A467T caused a
mild ptosis and R627Q/Q1236H caused early-onset ptosis and gait disturbance.
1.1 General symptoms of patients in studies I, III, IV
In study I the initial symptoms and signs of disease in the patients were ptosis,
progressive external ophthalmoplegia, and, in most individuals, peripheral
neuropathy, which was often painful; parkinsonism manifested several years later.
Most of the women had poorly developed secondary sex characteristics (breasts,
pubic hair) and they experienced primary or secondary amenorrhoea before the
onset of neurological symptoms. Cataracts were generally present. The
progressive external ophthalmoplegia in the patients was consistent with a muscle
disease. The patients also had typical muscle morphological findings of
mitochondrial myopathies such as ragged-red fibres. They responded positively to
levodopa treatment and its effect was long term.
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In study III we studied eight patients from five unrelated families. The patients
had adult or juvenile-onset sensory ataxic neuropathy in combination with various
central nervous system (CNS) abnormalities with no apparent skeletal muscle
involvement. Muscle biopsy samples showed no or minor signs of mitochondrial
disease in morphologic, biochemical or mtDNA analyses. Two of the eight
patients died at ages 36 and 39 years without extraocular muscle involvement. In
the other six patients, PEO was absent, although minor signs of PEO appeared at
a late disease stage in five.
In study IV, the patients of the Austrian family had clinical manifestations from
late-onset ptosis to early-onset ptosis together with gait disturbance. The index
patient was most severely affected having ataxia and early-onset PEO (IV).
However, long-range PCR did show only low levels of multiple mtDNA deletions in
skeletal muscles of index patient (IV).
2. POLG1 mutations in parkinsonism and in idiopathic
Parkinson’s disease (I, II)
2.1 POLG1 mutations associated with PEO, parkinsonism and premature
menopause (I)
In the  seven families four POLG1 mutations were identified, one of
which,Y955C, was previously described.130,138 Y955C was found in four families
(L,S,C,E) and it showed a dominant mode of inheritance, as all carriers were
affected (Figure 12). A new mutation in family N, R953C changed a conserved
amino acid at the polymerase active site motif polB (Figure 10). Another new
mutation, A1105T was present in families K and V. The second mutation in family
V, N468D, was found neither in controls nor in the literature, and it changed an
amino acid highly conserved in vertebrates. Co-segregation of parkinsonism with
POLG1 mutations was seen in five families (V,L,S,C,K). In families E and N,
parkinsonism was not detected. MtDNA analysis by Southern blotting was done in
muscle DNA of two patients, one carrying Y955C and the other having N468D in
trans with A1105T. Both patients had clearly multiple deletions of mtDNA (I).
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2.2 pol  variants in idiopathic Parkinson’s disease (II)
Significant clustering of rare non-10/11Q variants of the POLG1 CAG-repeat
(Figure 10), encoding a polyglutamine tract was found in Finnish idiopathic PD
patients (10%) as compared to their spouses (3.5%, p=0.003), population controls
(4.3%, p=0.001) and patients with other neuromuscular, non-parkinsonian
disorders (5.3%, p=0.05).  If all control groups are pooled together the frequency
of rare variants was 4.3% and Fisher’s Exact Test gave a two-tailed p-value of
0.0001. To determine the frequencies of non-10/11Q alleles in other populations
we pooled the data from previously published random Eurasian population
samples, which resulted in a frequency of 2.6% (76 out of 2922 chromosomes)
indicating that non-10/11Q alleles are relatively rare.150,195-198
Further, we found eight amino acid substitutions, but none of them were clearly
associated with PD since most of them were also found in spouse controls. A
novel missense change S1230F was found in one PD case, and this was not
present in 254 spouse control chromosomes, but the patient’s healthy aged sister
also carried this substitution. Four other novel amino acid variants were found.
Q49E substitution was found in cis with L392V in one PD case and two controls.
P241L and L392V were found in one control each. R722H was found in two PD
patients. One of them also had Q1236H and the other had a rare 12Q allele.
Three previously reported common coding region polymorphisms (Q1236H,
E1143G, K317K) were found in similar frequencies in PD patients and spouse
controls (12.5 vs. 16.5%, 1.8 vs. 2.4% and 1.1 vs. 1.2%, respectively, all p-values
>0.2). A previously reported variant Y831C 166 was found in combination with
Q1236H in one PD patient and as a single substitution in five controls.
Four locus analyses, utilizing the markers rs223829, L752L, rs2302084 and
Q1236H, failed to show evidence for a specific POLG1 haplotype association with
PD (global p>0.1; individual haplotype p-values >0.08). One individual haplotype
(9Q, rs223829=C, L752=C, rs2302084=A and Q1236=G) out of three had almost
4-fold frequency among PD patients vs. spouse controls (4.6% vs. 1.2%).
SNPHAP analysis revealed this haplotype in all of the 13 patients carrying 9Q and
in 3 spouse controls out of 5 carrying 9Q ( 2=4.93, 1df, nominal p=0.026), and
further analysis including the three 9Q associated haplotypes (13 patients and 5
controls) gave values of 2=2.49, 1df, p=0.11. Six PD patients carried two
combinations of pol  changes (6Q+E1143G, 9Q+9Q, 9Q+12Q, 12Q+R722H,
R722H+Q1236H, Y831C+Q1236H), and none of the 127 spouse controls had
such combinations (Figure 12).
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Figure 12. Summary of genetic findings in studies I and II. Based on study I, Y955C
and A1105T (bold) substitutions are associated with parkinsonism. Study II shows
association of rare polyglutamine alleles with idiopathic sporadic Parkinson’s disease. In
addition, different combinations of rare pol  variants were found in the Parkinson’s
















2.3 PolyQ variants and age of PD onset (unpublished data)
We analysed the effect of polyglutamine tract length on the age of onset in
Parkinson’s disease patients. These results suggest that the rare alleles may
affect the average age of disease onset. Carriers of the short alleles 8Q and 9Q
had later onset than those carrying the long alleles 12Q and 13Q (Figure 13).
Figure 13. Age of onset in idiopathic sporadic Parkinson’s disease patients.
Polyglutamine alleles were grouped in three classes and association of average
age-of-onset with polyQ length was analysed by Student’s t-test, the p-value given



































3. POLG1 spacer mutations associated with ataxia (III, IV)
3.1 POLG1 mutations in study III
In all patients we found recessive missense mutations in POLG1 (III). Seven
patients (six familial, one isolated) carried homozygous mutations, three for the
previously reported A467T and four for W748S. One isolated British patient was
compound heterozygous (A467T/W748S). A467T was a known mutation,138
whereas W748S was a novel pathogenic mutation in cis with E1143G. E1143G
alone is a previously reported common polymorphism. W748S and E1143G
always occurred together (four patients from two unrelated Finnish families,
Figure 14).
3.2 POLG1 mutations in study IV
We continued our studies with an Austrian family with various neurological
symptoms in three generations (IV). POLG1 sequence analysis showed three
amino acid changes: A467T and R627Q in cis with a polymorphic variant Q1236H
in the index patient. Two of these substitutions affected the spacer region (Figure
14). The phenotype resulting from the heterozygous A467T mutation was late-
onset ptosis without ophthalmoplegia. Patients with R627Q/Q1236H had early-
onset ptosis and gait disturbance.
The index patient, who was the most severely affected, carried all three
changes A467T in trans with R627Q/Q1236H. She displayed several CNS
manifestations, namely, ataxia, dysarthria, cognitive decline and nystagmus. She
also had early-onset PEO, sensory neuropathy and symptomatic restless legs
syndrome, which was responsive to treatment with L-dopa. Only sparse ragged-
red fibers were seen (<1%) in her muscle biopsy, and Southern blot analysis
showed normal-sized mtDNA. Amplification by long-PCR revealed the existence
of multiple deleted mtDNA molecules, which clearly exceeded the levels seen in
age-matched controls.
To study putative digenic effects in patients with late-onset ptosis
heterozygous for A467T,199 we sequenced the genes encoding ANT1, Twinkle-
helicase and 22 mtDNA encoding tRNAs, but did not identify additional mutations.
Furthermore, we excluded uneven expression of the two POLG1 alleles  by
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showing that the two allelic transcripts were present in equal proportions in the
patients lymphoblasts.
Figure 14. Summary of findings in studies III and IV. Study III identified new
mutations assoiated with  ataxia. Study IV identified new mutation associated with
ataxia+neuropathy+PEO. The common denominators in these studies were
substitutions in spacer region and additional ”polymorphic” substitutions
(underlined) in the polymerase domain, except in patients in study III who had
homozygous A467T substitutions. In both studies the major manifestation was
ataxia and neuropathy. Grey boxes below indicate the five pol  variants used in
biochemical in vitro studies. The A467T substitution clearly impaired DNA
polymerase gamma processivity, which was markedly improved by accessory
subunit pol . Large black arrowheads indicate homozygous state.
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4. Functional consequences of spacer mutations (IV)
In study IV we analysed for the first time effects of spacer region substitutions
A467T, R627Q and the previously reported R627W132 on DNA and accessory
subunit binding and polymerase activity and processivity. In addition, the effect of
polymorphic substitution Q1236H was analysed alone or in combination with
R627Q to detect a possible accumulative or modifying effect. In addition to
mutants described in the Austrian family, the R627W mutation was chosen
because it was shown to exhibit a recessive mode of inheritance whereas
R627Q/Q1236H mutant allele showed dominant inheritance. The idea was to
study biochemically a possible effect of Q1236H on causing R627Q to act as a
dominant mutation (Figure 14).
Pol  R627Q and R627W variants exhibited specific activities within the
normal range, but their DNA-binding affinities were modestly increased, as was
also processivity in the case of R627Q. Both DNA binding and processivity were
reduced in the A467T variant, and we therefore tested the effect of the pol -ß
subunit on this mutant. The polymerase activity of A467T was <20% of that of the
wild-type catalytic core, but, interestingly, accessory subunit pol  stimulated this
mutant ~20-fold, which was three to four times higher than the effect of the
accessory subunit on wildtype pol . Increased stimulation by pol  suggests
that its functional or physical interactions with pol  may compensate partially for
the biochemical defect of the A467T mutant in vitro.
We also compared the biochemical characteristics of R627Q and Q1236H in
combination and separately. When compared with the single R627Q mutant, the
double-mutant R627Q/Q1236H enzyme showed ~2-fold higher specific activity in
the gapped DNA assay and 1.6-fold higher activity in the ssDNA assay. In the
ssDNA assay, the accessory subunit stimulated both mutants similarly, such that
the difference in their specific activities remained 1.6-fold. Both processivity and




POLG1 mutations have been found to be the most frequent cause of the
autosomal dominant and recessive forms of PEO. The results presented in this
thesis show that POLG1 spacer and polymerase region mutations underlie new
common clinical phenotypes such as adult-onset recessive ataxia, parkinsonism
and premature menopause with recessive or dominant mode of inheritance (I, III,
IV, Figure 15). In addition, the preliminary results imply that the rare POLG1 cag-
repeat alleles might associate with idiopathic Parkinson’s disease (II).
We have shown that dominant and recessive mutations of POLG1 may lead to
PEO co-segregating with parkinsonism and premature menopause (I).
Thereafter, this finding has been confirmed by others. 153,200 PEO represents only
one clinical phenotypic expression of POLG1 mutations. The large differences
particularly in phenotypic expressions of recessive POLG1 mutations are
puzzling. Although PEO and sensory ataxia are common consequences of
POLG1 mutations, no single clinical feature is shared by all the patients.201
Speculations could be made about molecular causes of the observed clinical
heterogeneity. Data on familial patients suggest that clinical variability is more
marked between families than within families and the contribution of the genetic
background and its interaction with the environment may explain the observed
clinical heterogeneity. Interestingly, Redon et al. (2006) reported that 12 % of the
human genome involves copy number variants, which simply means that
individuals do not necessarily have one copy of a genomic region from their
mother and one from their father.202 Such variations are likely to have an impact
on disease manifestations and penetrance differences.
One of the major challenges for genetic counselling is the observation that
some mutations predicting specific amino acid substitutions can be either
dominant or recessive. Thus far there are at least three mutations which have
been shown to exhibit both dominant and recessive forms of inheritance:
mutations predicting A467T (III, IV), R627Q (IV and 134,158) and A1105T (I). Not
only for counselling but also for basic research it will be important and challenging
to find out what is the mechanism underlying this phenomenon. Actually,
sequencing can not detect all deletions, splice-site, promoter or intronic mutants,
and A1105T, for example, could hence be a recessive mutation combined with an
undetectable change. One possibility is that there is a mutation in another PEO
associated gene, i.e. a digenic inheritance of the disorder. In addition to
sequencing, messenger RNA (cDNA) of the POLG1 gene should be analysed,
both length to detect abnormal splicing and possible expression bias between
alleles. Large scale gene deletions should be analysed by Southern blotting.
Furthermore, the reported copy number variation202 should be analysed by
quantitative methods such as mini-sequencing.
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Figure 15. Summary of studies I-IV. POLG1mutations associate with new
clinical phenotypes with variable inheritance modes and penetrance
differences. Based on our (bold) and previous (underlined) studies by others, it
seems obvious that the same amino acid substitution can cause either dominant
(ad) or recessive (ar) disease (boxed). In addition, there are also indications that
different substitutions at the same position can cause either dominant or recessive
disease (circled). According to in vitro studies and genetic findings it seems possible
that the ”polymorphic” substitutions including rare polyglutamine variants (italics)
could have a cumulative pathogenic effect together with another substitution either
in cis (solid line)  or in trans, dashed lines indicate missing data whether
substitutions are in trans or in cis. Five Parkinson’s disease patients (PD), but none
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Analysis of the complete POLG1 gene sequence in 140 Finnish patients with
idiopathic sporadic PD showed clustering of rare polyglutamine length variants in
the PD subjects, compared to their spouses or healthy population controls and
almost 4-fold frequency compared to previously reported Eurasian controls
including Finns (II). We also analyzed pol  polyglutamine length variation in
Finnish patients with other neurodegenerative disorders of putative mitochondrial
origin. No clustering was detected in this mixed patient group, either. Overall, this
suggests a correlation between POLG1 encoded polyglutamine variants and
Finnish idiopathic PD. If these findings are confirmed in an independent cohort, it
could be estimated that approximately 5-10% of Finnish PD patients carry a
pathogenic POLG1 allele. We also showed that the length of rare polyglutamine
variants may have correlation with the age of disease onset. This phenomenon is
also well known in other neurodegenerative diseases caused by polyglutamine
tract expansions, such as Huntington’s disease and various spinocerebellar
ataxias.203
In 536 Finnish chromosomes PD patient and control chromosomes, we
detected altogether 17 coding region POLG1 variants of which five resulted in
novel missense changes. These included Q49E in cis with L392V in one PD
patient and two controls, suggesting that these two changes arose in one
ancestral chromosome. P241L was found in one control, L392V alone in one
control and R722H in two patients and one control. The S1230F variant was
encountered solely in a PD patient, and it exchanged a phenylalanine for a
conserved serine. However, the presence of the same variant in the patient’s
aged healthy sister suggests that this variant has no role in PD or that it has
reduced penetrance. All the novel variants had frequencies of <1% in the control
population, but none of them showed a clear association with PD. Furthermore,
common amino acid polymorphisms, such as E1143G and Q1236H, showed an
even distribution in our PD patients and spouse controls.  The many previously
unreported changes detected in this study suggest that either POLG1 is naturally
prone to undergo de novo mutagenesis, reflects the relatively small number of
previously analysed complete POLG1 gene sequences, or shows that specific
POLG1 alleles are enriched in the Finnish population.
Two previous studies have analyzed a partial POLG1 gene sequence in PD
patients. A study of 22 patients did not report a correlation between the polyQ
repeat length and PD.204 However, this series was too small to warrant
conclusions on genetic factors underlying a disorder involving several other
disease genes. The report did not mention the age of the controls, and the
samples were analyzed by polyacrylamide electrophoresis, which cannot detect
polyQ-alleles with amino acid substitutions, such as Q43R and Q49E. The other
study reported analysis of selected exons 7, 16, 18 and 21 of POLG1 in 140
unselected PD patients, and also failed to find PD-specific changes, although they
found two similar cases among 140 PD patients as we did (Y831C+Q1236H and
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9Q/9Q), these were seen neither in our nor their  controls. 171 Part of the
sequence analysis was done by dHPLC and the polyglutamine encoding region
was analyzed by capillary gel electrophoresis.  Based on our own experience and
published reports, dHPLC may fail to detect many of the POLG1 sequence
changes.128  These reports could not exclude the role of POLG1 in idiopathic PD.
Most cases of ataxia and POLG1 spacer mutations presented here (III,IV)
lacked all major signs of mitochondrial myopathies, such as ragged-red fibres or
mtDNA deletions in Southern blot or long-PCR analysis, leaving the mitochondrial
etiology of their disease undetected in routine histological and DNA analyses of
muscles.149,205,206 Since the accumulation of mtDNA deletions in tissues putatively
causes pathology,207 the absence of muscle mtDNA deletions in Southern blot
analysis correlates with the absence of clinical and morphologic abnormalities in
the muscle characteristic of PEO.
Up to date there are more than 30 confirmed homozygous W748S+E1143G
patients in Finland and quite likely several homozygous carriers who have not
been affected yet because of their young age. The W748S+E1143G associated
disorder was recently named as MIRAS (Mitochondrial Recessive Ataxia
Syndrome).111,208 Although the patients have the same homozygous mutation, the
clinical phenotypes are heterogenous with a characteristic set of features,
including ataxia, peripheral neuropathy, dysarthria, mild cognitive impairment,
involuntary movements, psychiatric symptoms, and epileptic seizures. According
to a recent report,209 the incidence of MIRAS is approximately 1 in 80 000, which
means an allele frequency of 0.35%. Consequently there are over 40 000
heterozygous carriers (1 in 125) and approximately 60 homozygous carriers in
Finland. There is also evidence suggesting that one heterozygous carrier might
also be affected mildly.172 The W748S+E1143G combination has also been found
in New Zealand, United States, Australia and Europe, and haplotyping has
revealed that they all share a single common ancient European ancestry.209
In ataxia, amino acid substitutions A467T, W748S, E1143G, Q1236H and
R627Q alter evolutionarily conserved amino acid residues (III, IV). The
contribution of E1143G to the phenotype remains unclear, although preliminary in
vitro functional assays show some altered biochemical characteristics,210 (IV).
Because E1143G is present in cis with W748S, it cannot be concluded that
W748S or E1143G alone is sufficient to cause disease in homozygous or
compound heterozygous patients. This situation is similar to the POLG1 mutations
T251I in cis with P587L in arPEO patients of different ethnic origins.149,155
Therefore, segregation analysis of novel low-frequency mutations remains crucial
to the determination of their pathogenic nature. In vivo functional studies on DNA
polymerase gamma are still unavailable and in vitro studies may not detect all
known and potential unknown functional defects, since functional studies include
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only a restricted set of experiments including DNA and accessory subunit binding
and polymerase activity and processivity studies.
All functional in vitro studies reported previously have been based solely on
analyses of dominant mutations affecting the polymerase domain of pol .
84,108,194 Our studies showed for the first time that the spacer region mutant,
A467T, has a clear and severe biochemical phenotype indicating impaired
polymerase function. This most likely results from reduced DNA binding and thus
affects the initiation of DNA strand elongation and attachment on the template
during elongation. Part of the pathogenic mechanism may be explained by
impaired interaction with the accessory subunit pol . Other mutations did not
show equally clear defects in their catalytic or DNA binding properties.
Substitutions affecting different regions of pol  have different pathogenic
mechanisms, which do not always directly affect the exonuclease or polymerase
functions of the enzyme.
We showed in vitro that a common polymorphism may have a modulating
effect on the biochemical characteristics of the pol  protein when occurring
alone or in combination with a pathogenic mutation (IV). Double mutant
R627Q/Q1236H had increased polymerase activity compared to R627Q alone.
The intriguing possibility remains that these sequence changes could have a
synergistic or accumulative effect on pol  function and it could be possible that
those proteins which have less impaired DNA or accessory subunit binding, act
more competitively because of their ability to compete better with wild-type protein
(dominant negative effect). A467T shows severely impaired DNA binding and
most likely has less competitive ability with wild-type to bind DNA in vivo (loss of
function effect). It could be possible that in mildly affected patients (A467T) there
are other physiological factors that might modify this binding capacity leading to
more competitive binding, and hence to mild clinical manifestation.
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Conclusions
We show in these studies that POLG1 mutations are relatively common causes of
neurodegenerative disorders. Our data that POLG1 mutations can also underlie
ataxia, parkinsonism/PD and premature menopause are essential for studies of
the genetics of these disorders and for clinicians diagnosing neuromuscular
diseases. Based on our results (I-IV), a POLG1 diagnostic routine has been set
up in Helsinki University Central Hospital (HUSLAB) and new POLG1 mutations
have been found in patients with neuromuscular disorders.
The position and nature of amino acid changes in pol  seem to have a
strong but incomplete correlation with the mode of inheritance and the clinical
manifestation, so that exo- and spacer mutations are predominantly recessive
whereas dominant mutations cluster mostly in the polymerase domain. The mode
of inheritance is occasionally ambigious; one mutation seems to have both
recessive and dominant modes of inheritance, although the existence of deletions,
intronic or promoter region mutations has not been excluded. In addition, a wide
spectrum of symptoms and degrees of penetrance can be detected in different
members of the same family, and even more evidently between different families
and/or sporadic cases. Furthermore, the muscular manifestations characteristic of
PEO are absent in some patients, for example in recessive spinocerebellar ataxia
syndrome (MIRAS) caused by a homozygous mutation predicting a W748S
substitution. On the other hand, the A467T substitution causes a wide variety of
severe clinical phenotypes in homozygous individuals between distinct families
with or  without PEO. This clinical  heterogeneity might  be due to different  sets of
polymorphic modifier genes between individuals.
Complete analyses of the POLG1 gene in 140 Finnish Parkinson’s disease
patients revealed a clear difference in rare polyglutamine variant frequencies
compared to pooled population controls. The question of whether these length
variants are pathogenic, risk factors or modifier genes needs to be studied further
by larger patient series, familial co-segregation studies and in vitro and in vivo
functional analysis.
Biochemical characterization of pathogenic amino acid substitutions in vitro
show that the spacer region of pol  has a potential role in template DNA binding
and could also have uncharacterized enzymatic function or functions not revealed
by the methods so far used. Furthermore, the common A467T substitution has a
clear defective biochemical phenotype, which is in accordance with the severe
clinical manifestations seen in homozygous patients. There is also evidence that
amino acid polymorphisms might have a role in POLG1 associated syndromes.
Our functional and genetic studies provide support for this hypothesis.
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Future prospects
Mutations in the POLG1 gene for the catalytic subunit of polG have been linked to
several mitochondrial disorders, including progressive external ophthalmoplegia,
sensory and ataxic neuropathy, Alpers syndrome and parkinsonism. Up to date,
over 80 pathogenic mutations have been identified in the POLG1 coding region.
The identification of POLG1 as a major disease locus for human mitochondrial
disorders has stimulated research on POLG1 and also highlighted a number of
mysteries in the biology of mtDNA and human disease. Since POLG1 mutations
have turned out to be a common source of a wide variety of distinct pathological
states, it would be of major interest to study in detail the molecular influence and
pathogenic mechanisms on the mtDNA and OXPHOS system both down- and
upstream. This research should also address the question of why some post-
mitotic tissues are not affected, i.e. what is the mechanism on avoiding defective
consequences. Detailed knowledge would be a prerequisite for rational
development of conceivable cure and medication for POLG-associated
syndromes. Mutations of POLG1 might provide unique opportunity to develop
treatments since, unlike other nuclear OXPHOS defects, there is a possibility to
study patient cohorts large enough, with a common denominator, i.e. with the
same mutation.
One of the major questions to be studied in the future is the mechanism of
mtDNA replication. Most of the essential proteins involved in mtDNA replication
have likely been identified, and reconstructed mtDNA replication forks have been
studied in vitro. This means that extensive functional studies both in vitro and in
vivo need to be conducted. Currently, there are two competing models of mtDNA
replication and further biochemical investigation is needed to develop a consistent
model. Studies of dysfunctional enzymes resulting from disease mutations should
yield new insights into the mechanism of mitochondrial DNA replication.
Furthermore, one crucial aspect in these studies would be the role of the structure
of substrate; mtDNA has a complex three-dimensional structure which could also
have multiple conformations related to gene expression, replication, repair and
other possibly metabolic factors.
One interesting and quite recent approach that has been applied successfully
is the new animal model, namely the domestic dog (Canis familiaris), which is
physiologically more similar to human than mouse. Due to inbreeding within
pedigrees, dogs have disorders resembling POLG1-associated syndromes seen
in humans, such as ataxia, tremor, neuro- and myopathies. (See Online
Mendelian Inheritance in Animals; http://omia.angis.org.au/). Quite likely they also
have mitochondrial disorders and pathogenic mutations in POLG1 or in other
known human disease orthologs, although the manifestations can be quite
different from humans.   Many breeds are well registered with detailed information
of pedigrees, which could help to find either new disease genes or mutations in
60
genes known to associate with human disorders. Another advantage would be the
availability of tissue material in order to accomplish distinct omics- and histological
studies and to develop and test treatments.
Exploitation of such animal models has also ethical advantages over
transgenic models. For example, even those who oppose transgenic animal
models seem to accept this approach, mostly because it is regarded as a sort of
“natural” inevitability like human diseases and it might also benefit animals if new
treatments could be developed on this basis.
Finally, the analysis of POLG1 mutations should be developed further, in
addition to sequencing of coding regions, also analysis of the allele copy
numbers, promoter region defects, intronic mutations and deletions should be
considered. Furthermore, also possible digenic mutations in other PEO-genes
should be analysed in the case of inheritance mode discrepancy.
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